Literature DB >> 12010634

Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis.

J R E Davis1, R F T McMahon, P R Lowenstein, M G Castro, G A Lincoln, A S McNeilly.   

Abstract

Gene therapy for pituitary disease requires evaluation for safety as well as efficacy. We have reported results of adenovirus-mediated gene transfer using the sheep as a large animal model that allows longitudinal evaluation of hormone secretion and have confirmed high levels of transgene expression up to 7 days after direct stereotaxic injection into the pituitary gland. Here we report the results of detailed histological examination of the pituitary glands from animals injected with two recombinant adenoviruses expressing the beta-galactosidase marker gene, or with saline vehicle to control for the potential tissue-disruptive effect of the injection volume itself. Pituitaries injected with saline showed no evidence of inflammatory response apart from occasional minor foci of apoptosis. In all other respects they were indistinguishable from normal uninjected control pituitary glands. Glands injected with recombinant adenoviruses containing either the hCMV-beta-gal or the hPRL-beta-gal transgene, on the other hand, displayed variable degrees of inflammatory response, with periglandular fibrosis, lymphocytic infiltrate and venulitis in almost all cases. Focal necrosis and/or apoptosis was noted in six of nine cases. In summary, we have found evidence of severe inflammatory reaction within the first seven days of adenovirus injection, amounting to significant hypophysitis. The histological extent of this reaction has not previously been recognised by studies of the efficacy of gene transfer in rodents, and was underestimated by immunocytochemical studies of hormone and transgene expression. The findings emphasise the need for careful evaluation of the safety of endocrine gene therapy, and for caution with the dose of vector used.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010634     DOI: 10.1677/joe.0.1730265

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS.

Authors:  Silvia S Rodriguez; Maria G Castro; Oscar A Brown; Rodolfo G Goya; Gloria M Console
Journal:  Expert Rev Endocrinol Metab       Date:  2009-07-01

2.  Induction of experimental autoimmune hypophysitis in SJL mice.

Authors:  Melissa A Landek-Salgado; Shey-Cherng Tzou; Hiroaki Kimura; Patrizio Caturegli
Journal:  J Vis Exp       Date:  2010-12-17       Impact factor: 1.355

3.  Adenohypophysitis in rat pituitary allografts.

Authors:  Fabio Rotondo; Andres Quintanar-Stephano; Sylvia L Asa; Matilde Lombardero; Istvan Berczi; Bernd W Scheithauer; Eva Horvath; Kalman Kovacs
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

Review 4.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

Review 5.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

6.  MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.

Authors:  Gerard V Walls; Manuel C Lemos; Mahsa Javid; Miriam Bazan-Peregrino; Jeshmi Jeyabalan; Anita A C Reed; Brian Harding; Damian J Tyler; Daniel J Stuckey; Sian Piret; Paul T Christie; Olaf Ansorge; Kieran Clarke; Len Seymour; Rajesh V Thakker
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.